Malignancy Risk: Is My Uterine Polyp Cancer?

For many patients, the most urgent question after finding a uterine polyp is: “Is it cancer?” It is important to know that the vast majority of uterine polyps are benign (non-cancerous) ^[1]. However, because a small percentage can contain precancerous or cancerous cells, doctors use a systematic approach to determine which polyps require immediate removal and tissue testing.

Understanding the Overall Risk

While the risk of malignancy is low, it is not zero. Across tens of thousands of patients in pooled studies, the overall average rate of cancer within a removed uterine polyp is approximately 2.73% ^[1]. If we include atypical hyperplasia (a precancerous condition), that pooled rate rises to about 3.4% ^[2].

It is vital to understand that these numbers are population averages from studies, not your exact personal risk. A benign polyp does not inevitably turn into cancer. Your individual risk changes based on your menopausal status, whether you have symptoms, and your personal medical history.

Risk by Life Stage and Symptoms

Doctors categorize polyps by the “clinical context” in which they are found. Research consistently shows that certain groups have a higher likelihood of finding abnormal cells ^[1][2]:

• Premenopausal Women: The risk is very low, with pooled study averages showing about 1.12% of evaluated polyps being malignant ^[1].
• Postmenopausal Women: The risk increases to approximately 4.93% in study averages ^[1].
• Symptomatic (Bleeding): If a polyp is causing bleeding, the risk of malignancy is higher (about 5.14% in pooled studies) ^[1].
• Asymptomatic (No Symptoms): If a polyp is found incidentally and is not causing symptoms, the risk is much lower (around 1.89%) ^[1].

Because of these differences, any bleeding after menopause is considered a significant clinical sign that requires prompt evaluation and usually the removal of the polyp for testing ^[3].

Other Influencing Factors

Beyond age and symptoms, certain health factors influence a clinician’s concern about a polyp:

• Obesity and Diabetes: Both conditions are known risk factors for overall endometrial cancer. Evidence suggests they may also influence the risk of atypia or cancer within a polyp, lowering a doctor’s threshold to recommend removal ^[2][4].
• Tamoxifen Use: Patients taking tamoxifen for breast cancer treatment have an increased risk of developing endometrial abnormalities. While tamoxifen does not automatically make every polyp malignant, it is an important risk factor that warrants individualized discussion ^[2].
• Polyp Size: In some cases, polyps larger than 2 centimeters are considered to have a higher potential for harboring abnormal cells, leading many doctors to recommend their removal even if they don’t cause symptoms ^[3][5].

Reading the Pathology Report

If your polyp is removed, a pathologist will examine it under a microscope. You may see various terms on your report. Understanding these “red flag” terms can help you prepare for a conversation with your doctor:

• Benign / Negative for Malignancy: The cells are completely normal. No further cancer treatment is needed.
• Hyperplasia without atypia: The lining is thickened, but the cells do not look cancerous. This is generally lower risk, but may still require surveillance or treatment with progestin medications ^[6].
• Atypical Hyperplasia or EIN (Endometrial Intraepithelial Neoplasia): These are precancerous terms. The cells look abnormal and crowded. This requires prompt gynecologic review. For patients who have completed childbearing, a hysterectomy is often recommended as a definitive cure. However, for highly selected patients wishing to preserve fertility, specialist care using progestin therapy and very close repeat biopsies may be an option ^[6][7].
• Adenocarcinoma: This is the most common form of endometrial cancer. If found, prompt referral to a gynecologic oncologist is required ^[8].
• Serous Carcinoma: A less common but more aggressive type of cancer. Even if only found within a tiny polyp, it requires extensive evaluation by an oncologist ^[9][10].

Summary of Evaluation Guidelines

Current medical guidelines recommend individualized assessment based on bleeding, size, and risk factors. Prompt tissue evaluation is highly prioritized in the following scenarios ^[3]:

1. Postmenopausal bleeding where a polyp is detected.
2. Premenopausal abnormal bleeding causing significant symptoms.
3. Asymptomatic postmenopausal polyps that are larger than 2 cm or occur alongside other cancer risk factors.